Education

Ph.D in Virology, University of Leuven, Belgium, 1993

Current position

Full professor, Virology and Chemotherapy section, Rega Institute, University of Leuven
Research interests: Development of novel antiviral strategies www.rega.kuleuven.be/cmt/jn

Publications (selected)

1. Wang, Y., Zhou, X., Debing, Y., Chen, K., Van Der Laan, L. J., Neyts, J., Janssen, H. L., Metselaar, H. J., Peppelenbosch, M. P. and Pan, Q. (2014). Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology 146(7): 1775-1783.
   
2. Debing, Y. and Neyts, J. (2014). mTOR-inhibitors may aggravate chronic hepatitis E. J Hepatol. (Epub ahead of print)
   
3. Thibaut, H. J., van der Linden, L., Jiang, P., Thys, B., Canela, M. D., Aguado, L., Rombaut, B., Wimmer, E., Paul, A., Perez-Perez, M. J., van Kuppeveld, F. J. and Neyts, J. (2014). Binding of glutathione to enterovirus capsids is essential for virion morphogenesis. PLoS Pathog 10(4): e1004039.
   
4. Debing, Y., Emerson, S. U., Wang, Y., Pan, Q., Balzarini, J., Dallmeier, K. and Neyts, J. (2014). Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrob Agents Chemother 58(1): 267-273.
   
5. Rocha-Pereira, J., Jochmans, D., Debing, Y., Verbeken, E., Nascimento, M. S. and Neyts, J. (2013). The viral polymerase inhibitor 2'-C-methylcytidine inhibits Norwalk virus replication and protects against norovirus-induced diarrhea and mortality in a mouse model. J Virol 87(21): 11798-11805.
   
6. Debing, Y., Winton, J., Neyts, J. and Dallmeier, K. (2013). Cutthroat trout virus as a surrogate in vitro infection model for testing inhibitors of hepatitis E virus replication. Antiviral Res 100(1): 98-101.
   
7. Debing, Y., Jochmans, D. and Neyts, J. (2013). Intervention strategies for emerging viruses: use of antivirals. Curr Opin Virol 3(2): 217-224.
   
8. Delang, L., Vliegen, I., Leyssen, P. and Neyts, J. (2012). In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors. J Hepatol 56(1): 41-48.
   
9. Paeshuyse, J., Dallmeier, K. and Neyts, J. (2011). Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr Opin Virol 1(6): 590-598.
   
10. Kaptein, S. J., De Burghgraeve, T., Froeyen, M., Pastorino, B., Alen, M. M., Mondotte, J. A., Herdewijn, P., Jacobs, M., de Lamballerie, X., Schols, D., Gamarnik, A. V., Sztaricskai, F. and Neyts, J. (2010). A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro. Antimicrob Agents Chemother 54(12): 5269-5280.
    
11. Delang, L., Paeshuyse, J., Vliegen, I., Leyssen, P., Obeid, S., Durantel, D., Zoulim, F., Op de Beeck, A. and Neyts, J. (2009). Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology 50(1): 6-16.
    
12. De Palma, A. M., Thibaut, H. J., van der Linden, L., Lanke, K., Heggermont, W., Ireland, S., Andrews, R., Arimilli, M., Al-Tel, T. H., De Clercq, E., van Kuppeveld, F. and Neyts, J. (2009). Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob Agents Chemother 53(5): 1850-1857.
    
13. Coelmont, L., Kaptein, S., Paeshuyse, J., Vliegen, I., Dumont, J. M., Vuagniaux, G. and Neyts, J. (2009). Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother 53(3): 967-976.
    
14. Paeshuyse, J., Vliegen, I., Coelmont, L., Leyssen, P., Tabarrini, O., Herdewijn, P., Mittendorfer, H., Easmon, J., Cecchetti, V., Bartenschlager, R., Puerstinger, G. and Neyts, J. (2008). Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. Antimicrob Agents Chemother 52(9): 3433-3437.
    
15. De Palma, A. M., Purstinger, G., Wimmer, E., Patick, A. K., Andries, K., Rombaut, B., De Clercq, E. and Neyts, J. (2008). Potential use of antiviral agents in polio eradication. Emerg Infect Dis 14(4): 545-551.
    
16. De Palma, A. M., Heggermont, W., Lanke, K., Coutard, B., Bergmann, M., Monforte, A. M., Canard, B., De Clercq, E., Chimirri, A., Purstinger, G., Rohayem, J., van Kuppeveld, F. and Neyts, J. (2008). The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C. J Virol 82(10): 4720-4730.
    
17. Leyssen, P., De Clercq, E. and Neyts, J. (2008). Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res 78(1): 9-25.
    
18. Paeshuyse, J., Chezal, J. M., Froeyen, M., Leyssen, P., Dutartre, H., Vrancken, R., Canard, B., Letellier, C., Li, T., Mittendorfer, H., Koenen, F., Kerkhofs, P., De Clercq, E., Herdewijn, P., Puerstinger, G., Gueiffier, A., Chavignon, O., Teulade, J. C. and Neyts, J. (2007). The imidazopyrrolopyridine analogue AG110 is a novel, highly selective inhibitor of pestiviruses that targets the viral RNA-dependent RNA polymerase at a hot spot for inhibition of viral replication. J Virol 81(20): 11046-11053.
    
19. Coelmont, L., Paeshuyse, J., Windisch, M. P., De Clercq, E., Bartenschlager, R. and Neyts, J. (2006). Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine. Antimicrob Agents Chemother 50(10): 3444-3446.
    
20. Leyssen, P., De Clercq, E. and Neyts, J. (2006). The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Mol Pharmacol 69(4): 1461-1467.
    
21. Paeshuyse, J., Kaul, A., De Clercq, E., Rosenwirth, B., Dumont, J. M., Scalfaro, P., Bartenschlager, R. and Neyts, J. (2006). The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43(4): 761-770.
    
22. Paeshuyse, J., Leyssen, P., Mabery, E., Boddeker, N., Vrancken, R., Froeyen, M., Ansari, I. H., Dutartre, H., Rozenski, J., Gil, L. H., Letellier, C., Lanford, R., Canard, B., Koenen, F., Kerkhofs, P., Donis, R. O., Herdewijn, P., Watson, J., De Clercq, E., Puerstinger, G. and Neyts, J. (2006). A novel, highly selective inhibitor of pestivirus replication that targets the viral RNA-dependent RNA polymerase. J Virol 80(1): 149-160.
    
23. Stittelaar, K. J., Neyts, J., Naesens, L., van Amerongen, G., van Lavieren, R. F., Holy, A., De Clercq, E., Niesters, H. G., Fries, E., Maas, C., Mulder, P. G., van der Zeijst, B. A. and Osterhaus, A. D. (2006). Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature 439(7077): 745-748.
    
24. Ying, C., Holy, A., Hockova, D., Havlas, Z., De Clercq, E. and Neyts, J. (2005). Novel acyclic nucleoside phosphonate analogues with potent anti-hepatitis B virus activities. Antimicrob Agents Chemother 49(3): 1177-1180.
    
25. Leyssen, P., Balzarini, J., De Clercq, E. and Neyts, J. (2005). The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 79(3): 1943-1947.